Staffed 24 hours a day, 365 days a year
Technical Directors: Marcy Bauman, PhD; Danbin Xu, MD, PhD
PAML offers a wide range of molecular-based technologies to improve patient care by providing highly sensitive and specific testing and timely result reporting.
Molecular testing makes it possible not only to diagnose specific genetic, pathogenic, and oncologic diseases but also to monitor a patient’s disease over time, a feature that allows for timely patient management and treatment decisions. Furthermore, molecular genetic testing provides highly accurate negative-predictive values when screening for genetic mutations in cystic fibrosis and other diseases.
PAML’s molecular diagnostics laboratory offers DNA storage capabilities.
The latest recommendations from the Cytopathology Education and Testing Consortium (CETC), published in the June 25, 2009 issue of the journal "Cancer Cytopathology"
Click here to read "Statement on Human Papillomavirus DNA Test Utilization"
Click here to read "Brief Guidance...Appropriate Use of HPV by CETC"
We also offer nucleic acid-based testing for the diagnosis of select genetic, infectious disease and oncologic anomalies including:
We provide a full range of molecular diagnostic and consulting services for adult, pediatric, and prenatal cases. We are committed to provide the highest quality of patient care and serve as competent and easily available consultants to our referring physicians. The molecular diagnostics laboratory staff includes a board-certified medical geneticist, who is available for consultation.
PAML has a strategic alliance with Roche Diagnostics, the world’s leading diagnostics company. PAML, together with Roche, has established a Molecular Center of Excellence (MCOE) for molecular diagnostics and other advanced genomic technologies. Access to Roche’s vast resources has helped PAML bring this emerging technology to our healthcare communities.